Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175060 | 0.91 | PTGS2 (0.51) | PTGS2TSHRPOLBHSD17B10KDM4E | |
| SCHEMBL9430367 | 0.78 | LMNA (0.51) | TSHRPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL6065023 | 0.78 | CYSLTR2 (0.56) | PTGS2EPHX2CYSLTR2CYSLTR1HPGD | |
| SCHEMBL27261843 | 0.78 | CYSLTR2 (0.56) | PTGS2EPHX2CYSLTR2CYSLTR1HPGD | |
| SCHEMBL26240068 | 0.76 | CYP4F2 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL9727526 | 0.76 | APOBEC3G (0.53) | PTGS2EPHX2NPSR1CYSLTR2CYSLTR1 | |
| SCHEMBL1554320 | 0.75 | KDM4E (0.53) | TSHRPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL28366194 | 0.74 | TSHR (0.51) | TSHRHSD17B10KDM4ENPSR1ALDH1A1 | |
| SCHEMBL9891121 | 0.74 | KDM4E (0.45) | TSHRPOLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL28267934 | 0.74 | LIPG (0.51) | PTGS2CYSLTR2CYSLTR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | PTGS2 2310/4885EPHX2 3281/4885TSHR 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.